Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
Andrew M Blumenfeld, Benjamin M Frishberg, Jack D Schim, Ashley Iannone, Gary Schneider, Larisa Yedigarova, Aubrey Manack Adams, Andrew M Blumenfeld, Benjamin M Frishberg, Jack D Schim, Ashley Iannone, Gary Schneider, Larisa Yedigarova, Aubrey Manack Adams
Abstract
Introduction: Combination use of onabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) has the potential to be more effective than either therapy alone for migraine prevention.
Methods: This retrospective, longitudinal chart review included adults with chronic migraine treated at one clinical site with ≥ 2 consecutive cycles of onabotulinumtoxinA and ≥ 1 month of subsequent combination treatment with CGRP mAbs. Charts at time of mAb prescription (baseline) and up to four visits ~ 3, 6, 9, and 12 months post-baseline were reviewed for safety, tolerability, and outcome measures (monthly headache days [MHDs], headache intensity, and migraine-related disability [MIDAS]).
Results: Of 300 charts reviewed, 257 patients met eligibility criteria (mean age: 50 years; 82% women). Average headache frequency was 21.5 MHDs before initiation of onabotulinumtoxinA and 12.1 MHDs before adding CGRP mAb therapy. Prescribed mAbs were erenumab (78%), fremanezumab (6%), and galcanezumab (16%). Over the entire study, patients discontinued CGRP mAb more frequently than onabotulinumtoxinA (23 vs. 3%). Adverse events occurred in 28% of patients, most commonly constipation (9%). Compared with onabotulinumtoxinA alone (baseline), MHDs decreased significantly at all visits (mean decrease: 3.5-4.0 MHDs over ~ 6-12 months of combination treatment); 45.1% of patients had clinically meaningful improvement in migraine-related disability (≥ 5-point reduction in MIDAS score) after ~ 6 months.
Conclusions: In this real-world study, combination treatment with onabotulinumtoxinA and CGRP mAbs was well tolerated, with no new safety signals identified, and was associated with additional clinically meaningful benefits. More real-world and controlled trials should be considered to further assess safety and potential benefits of combination treatment. Video abstract: Real-world data suggests that CGRP inhibitors improve onabotulinumtoxinA efficacy for chronic migraine (MP4 20,067 kb).
Keywords: CGRP receptor; Chronic daily headache; Chronic headache; Combination therapy; Migraine headache; Preventive treatment; Type A botulinum toxins.
© 2021. The Author(s).
Figures
References
- IHS classification ICHD-3: migraine. 2019. . Accessed 18 Feb 2020.
- Lipton RB, Manack Adams A, Buse DC, Fanning KM, Reed ML. A comparison of the chronic migraine epidemiology and outcomes (CaMEO) study and American migraine prevalence and prevention (AMPP) study: demographics and headache-related disability. Headache. 2016;56:1280–1289. doi: 10.1111/head.12878.
- Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS) Cephalalgia. 2011;31:301–315. doi: 10.1177/0333102410381145.
- Buse DC, Manack Adams A A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry. 2010;81:428–432. doi: 10.1136/jnnp.2009.192492.
- Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;59:1286–1299. doi: 10.1111/head.13613.
- Lanteri-Minet M, Duru G, Mudge M, Cottrell S. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia. 2011;31:837–850. doi: 10.1177/0333102411398400.
- Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. doi: 10.1177/0333102410364676.
- Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. doi: 10.1177/0333102410364677.
- Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19:13. doi: 10.1186/s10194-018-0840-8.
- Rothrock JF, Manack Adams A, Lipton RB, et al. FORWARD study: evaluating the comparative effectiveness of onabotulinumtoxinA and topiramate for headache prevention in adults with chronic migraine. Headache. 2019;59:1700–1713. doi: 10.1111/head.13653.
- Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P. An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. J Headache Pain. 2019;20:26. doi: 10.1186/s10194-019-0976-1.
- Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of action of onabotulinumtoxinA in chronic migraine: a narrative review. Headache. 2020;60:1259–1272. doi: 10.1111/head.13849.
- Durham PL. CGRP-receptor antagonists—a fresh approach to migraine therapy? N Engl J Med. 2004;350:1073–1075. doi: 10.1056/NEJMp048016.
- Joussain C, Le Coz O, Pichugin A, et al. Botulinum neurotoxin light chains expressed by defective herpes simplex virus type-1 vectors cleave SNARE proteins and inhibit CGRP release in rat sensory neurons. Toxins (Basel). 2019;11:123. doi: 10.3390/toxins11020123.
- Cernuda-Morollón E, Ramón C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156:820–824. doi: 10.1097/j.pain.0000000000000119.
- Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338–350. doi: 10.1038/s41582-018-0003-1.
- Aimovig [package insert]. Thousand Oaks, CA, and East Hanover, NJ: Amgen Inc., and Novartis Pharmaceuticals Corporation; 2020.
- Ajovy [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2020.
- Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
- Pellesi L, Do TP, Ashina H, Ashina M, Burstein R. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60:1056–1065. doi: 10.1111/head.13843.
- Melo-Carrillo A, Strassman AM, Nir RR, et al. Fremanezumab—A humanized monoclonal anti-CGRP antibody—inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37:10587–10596. doi: 10.1523/JNEUROSCI.2211-17.2017.
- Melo-Carrillo A, Strassman AM, Schain AJ, et al. Exploring the effects of extracranial injections of botulinum toxin type A on prolonged intracranial meningeal nociceptors responses to cortical spreading depression in female rats. Cephalalgia. 2019;39:1358–1365. doi: 10.1177/0333102419873675.
- Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. Erenumab and onabotulinumtoxinA combination therapy for the prevention of intractable chronic migraine without aura: a retrospective analysis. J Pain Palliat Care Pharmacother. 2020 doi: 10.1080/15360288.2020.1829249.
- Boudreau GP. Treatment of chronic migraine with erenumab alone or as an add on therapy: a real-world observational study. Anesth Pain Res. 2020;4:1–4. doi: 10.33425/2639-846X.1037.
- Cohen F, Armand C, Vollbracht S. Efficacy and tolerability of CGRP monoclonal antibody medications in patients with chronic migraine undergoing treatment with onabotulinumtoxinA [poster]. Annual Meeting of the American Headache Society; 2020 June 13, 2020.
- Gottschalk PC, Henn K, Robinson J, Schobel VR. Anti-CGRP class reduces migraine burden regardless of concomitant therapies in US clinical practice [poster]. Annual Meeting of the American Academy of Neurology; 2020.
- Suri H, Nandyala A, Dougherty C, Ailani J. Combination of erenumab and onabotulinum toxin A is a safe and effective treatment for chronic migraine [poster]. Annual Meeting of the American Headache Society; 2020 June 13, 2020.
- Singh S, Singh H, Govindarajan R. Galcanezumab in the prevention of chronic migraine in patients on botulinum toxin therapy [abstract] Neurology. 2020;94(15 suppl):5257.
- Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ. Real-world patient experience with erenumab for the preventive treatment of migraine. Headache. 2020;60:2014–2025. doi: 10.1111/head.13951.
- Ozudogru SN, Bartell JW, Yuan H, Digre KB, Baggaley SK. The effect of adding calcitonin gene-related peptide monoclonal antibodies to onabotulinum toxin A therapy on headache burden: a retrospective observational case series. Headache. 2020;60:1442–1443. doi: 10.1111/head.13839.
- American Headache Society The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1–18.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
- Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56:S20–S28. doi: 10.1212/WNL.56.suppl_1.S20.
- Lipton RB, Desai P, Sapra S, Buse DC, Fanning KM, Reed ML. How much change in headache-related disability is clinically meaningful? Estimating minimally important difference (MID) or change in MIDAS using data from the AMPP study [abstract PF52] Headache. 2017;57:165–166. doi: 10.1111/head.12997.
- Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123–2132. doi: 10.1056/NEJMoa1705848.
- Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026–1037. doi: 10.1177/0333102418759786.
- Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425–434. doi: 10.1016/S1474-4422(17)30083-2.
- Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211–e2221. doi: 10.1212/WNL.0000000000006640.
- Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080–1088. doi: 10.1001/jamaneurol.2018.1212.
- Pietrobon D, Moskowitz MA. Pathophysiology of migraine. Annu Rev Physiol. 2013;75:365–391. doi: 10.1146/annurev-physiol-030212-183717.
- Armanious M, Khalil N, Lu Y, Jimenez-Sanders R. A retrospective analysis to evaluate the response of the addition of erenumab to onabotulinumtoxinA for the prevention of intractable chronic migraine without aura [poster]. Annual Meeting of the American Headache Society; 2019 July 11–14, 2019; Philadelphia, PA.
- Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999–2008. doi: 10.1001/jama.2018.4853.
- Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113–2122. doi: 10.1056/NEJMoa1709038.
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936. doi: 10.1111/j.1526-4610.2010.01678.x.
- Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394:1030–1040. doi: 10.1016/S0140-6736(19)31946-4.
- Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280–2287. doi: 10.1016/S0140-6736(18)32534-0.
- Mulleners W, Kim B, Lainez M, et al. A randomized, placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: double-blind results from the CONQUER study [abstract] Neurology. 2020;94:162. doi: 10.1212/WNL.0000000000008834.
- Goadsby PJ, Paemeleire K, Broessner G, et al. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2019;39:817–826. doi: 10.1177/0333102419835459.
Source: PubMed